Antibodies to infliximab in patients with Crohn's disease do not cross-react with certolizumab pegol

被引：0
|
作者：
Vetterlein, O. [1 ]
Kopotsha, T. M. [1 ]
Nesbitt, A. M. [1 ]
Brown, D. T. [1 ]
Stephens, S. [1 ]
机构：
[1] Celltech Antibody Ctr Excellence, Antibody Biol Div, Slough, Berks, England
来源：
GUT | 2007年 / 56卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
356
引用
收藏
页码：A116 / A116
页数：1
相关论文
共 50 条
  • [1] Antibodies to certolizumab pegol in patients with Crohn's disease do not cross-react with adalimumab, etanercept, or infliximab
    Vetterlein, Olivia M.
    Nesbitt, Andrew M.
    Stephens, Sue
    GASTROENTEROLOGY, 2007, 132 (04) : A556 - A556
  • [2] Anti-infliximab antibodies in Crohn's disease patients are specific and do not cross-react with other therapeutic antibodies
    Rojas, JR
    McCabe, D
    Diamond, RH
    Wagner, C
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2004, 99 (10): : S251 - S251
  • [3] In patients suffering from Crohn's disease, no cross reaction between antibodies to infliximab and certolizumab pegol was detected
    Nesbitt, Andrew M.
    Vetterlein, Olivia M.
    Kopotsha, Tim M. T.
    Brown, Derek T.
    Stephens, Sue
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2006, 101 (09): : S437 - S438
  • [4] CERTOLIZUMAB PEGOL IN CROHN'S DISEASE REFRACTORY TO INFLIXIMAB AND ADALIMUMAB
    Jose, Morales Lara Ma
    Penella Monica, Martinez
    Guzman Diana, Lacruz
    Vidal Vanessa, Jorge
    Maneiro Vicente, Santaclara
    Sanchez Senador, Moran
    del Carmen, Mira Sirvent Ma
    ATENCION FARMACEUTICA, 2009, 11 (03): : 178 - 180
  • [5] In patients with rheumatoid arthritis treated with the anti-TNF certolizumab pegol or infliximab, antibodies produced do not cross react with other reagents
    Vetterlein, O.
    Kopotsha, T.
    Nesbitt, A.
    Brown, D.
    Stephens, S.
    ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 : 161 - 161
  • [6] Certolizumab Pegol in Patients With Moderate to Severe Crohn's Disease and Secondary Failure to Infliximab
    Sandborn, William J.
    Abreu, Maria T.
    D'Haens, Geert
    Colombel, Jean-Frederic
    Vermeire, Severine
    Mitchev, Krassimir
    Jamoul, Corinne
    Fedorak, Richard N.
    Spehlmann, Martina E.
    Wolf, Douglas C.
    Lee, Scott
    Rutgeerts, Paul
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2010, 8 (08) : 688 - 695
  • [7] Neutralising antibodies to certolizumab pegol do not appear to impact on efficacy or safety in patients with crohn's disease
    Nesbitt, A. M.
    Stephens, S.
    Bloomfield, R.
    GUT, 2008, 57 : A142 - A142
  • [8] Efficacy and safety of certolizumab pegol do not appear to be affected by neutralizing antibodies in patients with Crohn's disease
    Stephens, Sue
    Bloomfield, Ralph
    Devine, Donna M.
    Nesbitt, Andrew M.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2007, 102 : S475 - S475
  • [9] Neutralizing antibodies to certolizumab pegol do not appear to affect efficacy and safety in patients with Crohn's disease
    Stephens, S.
    Bloomfield, R.
    Devine, D.
    Nesbitt, A.
    INFLAMMATORY BOWEL DISEASES, 2008, 14 (01) : S27 - S27
  • [10] Certolizumab pegol in Crohn's disease
    Blick, Stephanie K. A.
    Curran, Monique P.
    BIODRUGS, 2007, 21 (03) : 195 - 201
12345